Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects

Circulation

Volumn 107, Issue 14, 2003, Pages 1891-1895

  Kielstein, Jan T ^a   Bode Böger, Stefanie M ^b   Frölich, Jürgen C ^a   Ritz, Eberhard ^c   Haller, Hermann ^a   Fliser, Danilo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aging; Hypertension; Kidney; Nitric oxide synthase

Indexed keywords

ARGININE; GLUCOSE; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENESCENCE; STEREOISOMERISM;

ADULT; AGED; AGING; ARGININE; BLOOD PRESSURE; FEMALE; GLOMERULAR FILTRATION RATE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; KIDNEY; MALE; RENAL CIRCULATION; RENAL PLASMA FLOW, EFFECTIVE;

EID: 0344088466     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000060496.23144.A7     Document Type: Article

References (41)

1. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol. 1997;30:325-333.
2. Chauhan A, More RS, Mullins PA, et al. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. J Am Coll Cardiol. 1996;28:1796-1804.
3. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
4. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000;20:2032-2037.
5. Boger RH, Bode-Boger SM, Thiele W, et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95:2068-2074.
6. Kielstein JT, Boger RH, Bode-Boger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10:594-600.
7. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141-1146.
8. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127-2128.
9. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet. 2001;358:2096-2097.
10. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 2001;158:425-430.
11. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 2002;13:490-496.
12. Kielstein JT, Frolich JC, Haller H, et al. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol Dial Transplant. 2001;16:1742-1745.
13. Fliser D, Zeier M, Nowack R, et al. Renal functional reserve in healthy elderly subjects. J Am Soc Nephrol. 1993;3:1371-1377.
14. Fliser D, Franek E, Joest M, et al. Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int. 1997;51:1196-1204.
15. Hollenberg NK, Adams DF, Solomon HS, et al. Senescence and the renal vasculature in normal man. Circ Res. 1974;34:309-316.
16. Fuiano G, Sund S, Mazza G, et al. Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. Kidney Int. 2001;59:1052-1058.
17. Campo C, Lahera V, Garcia-Robles R, et al. Aging abolishes the renal response to L-arginine infusion in essential hypertension. Kidney Int Suppl. 1996;55:S126-S128.
18. Higashi Y, Oshima T, Ozono R, et al. Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. Hypertension. 1997;30:252-258.
19. Kuehnle HF, von DK, Schmidt FH. Fully enzymatic inulin determination in small volume samples without deproteinization. Nephron. 1992;62:104-107.
20. Cody RJ, Torre S, Clark M, et al. Age-related hemodynamic, renal, and hormonal differences among patients with congestive heart failure. Arch Intern Med. 1989;149:1023-1028.
21. Schmieder RE, Schachinger H, Messerli FH. Accelerated decline in renal perfusion with aging in essential hypertension. Hypertension. 1994;23:351-357.
22. Sabbatini M, Sansone G, Uccello F, et al. Functional versus structural changes in the pathophysiology of acute ischemic renal failure in aging rats. Kidney Int. 1994;45:1355-1361.
23. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol. 1996;270:F845-F851.
24. Broere A, Van Den Meiracker AH, Boomsma F, et al. Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME. Am J Physiol. 1998;275:F870-F877.
25. Lahera V, Salom MG, Miranda-Guardiola F, et al. Effects of NG-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol. 1991;261:F1033-F1037.
26. Gardiner SM, Kemp PA, Bennett T, et al. Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol. 1993;110:1457-1464.
27. Segarra G, Medina P, Vila JM, et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens. 2001;14:1142-1148.
28. Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension. 1999;33:937-942.
29. Xiong Y, Yuan LW, Deng HW, et al. Elevated serum endogenous inhibitor of nitric oxide synthase and endothelial dysfunction in aged rats. Clin Exp Pharmacol Physiol. 2001;28:842-847.
30. Xiao S, Wagner L, Schmidt RJ, et al. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int. 2001;59:1466-1472.
31. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
32. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.
33. Fard A, Tuck CH, Donis JA, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000;20:2039-2044.
34. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113-2117.
35. Tojo A, Welch WJ, Bremer V, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1997;52:1593-1601.
36. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol. 2002;13:170-176.
37. Xiao ZS, Quarles LD, Chen QQ, et al. Effect of asymmetric dimethylarginine on osteoblastic differentiation. Kidney Int. 2001;60:1699-1704.
38. Boger RH, Lentz SR, Bode-Boger SM, et al. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond). 2001;100:161-167.
39. Stuhlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575.
40. Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99:3092-3095.
41. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420-1426.